Ligand Pharmaceuticals (LGND) Q3 2026 earnings review
Ligand's drug royalties jump 51%, but deal costs erase profit
Ligand Pharmaceuticals, which buys rights to a share of drug sales, grew its royalty stream while acquisition costs and investment writedowns created a loss under standard accounting. Royalty revenue jumped 51% to $70 million as chief executive Todd Davis folded in the XOMA portfolio in July, lifting total revenue 26% once last year's Pelthos unit sale is stripped out. The company raised its full-year profit target excluding one-offs for a third time, which by our math implies $2.96 per share in the fourth quarter.
| Total revenue excluding Pelthos sale | $78.7M +26% from a year ago |
|---|---|
| Royalty revenue | $70.3M +51% from a year ago |
| Profit per share, excluding one-offs | $2.67 -14% from a year ago (+13% from Q2) |
| Full-year profit per share outlook | Raised $0.38 middle of the range: $9.63 (+18%) |
⚖️ Verdict: 🟢 Bullish
The story got better because the first quarter with XOMA lifted quarterly royalties by $22 million from the second quarter and supported another raise to the full-year profit plan. One caution: general and administrative overhead excluding stock awards and deal fees still more than doubled from a year ago to $20 million by our math, and the release did not separate XOMA's royalties from existing drugs.
The question now is how much of the royalty jump came from underlying drug growth versus the XOMA purchase, and whether the higher overhead is permanent. Either the expanded deal team will drive faster royalty compounding at low ongoing cost, or rising overhead and investment marks will keep eating into accounting profit. The third-quarter 10-Q filing's product breakdown and the five-year plan at the December 8 investor day will settle both.
🐂 Bull Case
XOMA Purchase Lifts Royalties Above $70 Million
Ligand buys rights to a share of drug sales, known as royalties, in exchange for funding drug developers. On July 14 it closed the purchase of rival aggregator XOMA Royalty, doubling its portfolio to over 200 drug programs and adding seven marketed medicines.
- Total royalty revenue: $70.3 million, up 50.9% from a year ago and up $22.3 million from last quarter by our math
- Income from financial royalty assets (contracts treated as financing assets): $22.9 million, up 255.8% from a year ago
- Intangible royalty revenue (traditional royalty contracts): $47.4 million, up 18.1% from a year ago
- Deployable capital: about $750 million available for future deals, including credit lines
Chief executive Todd Davis said the XOMA portfolio and kidney drug Filspari drove the 51% royalty increase. The aggregator also kept buying, "acquiring a royalty interest in Santen’s Ryjunea and entering into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline" for $23 million upfront and up to $47 million in commitments.
What to watch: the five-year royalty outlook at the December 8 investor day. A target above the prior 23% yearly growth goal would show that the XOMA deal raised the long-term growth trajectory.
Third Profit Target Raise This Year
Ligand tracks profit per share excluding one-offs, a measure its board uses to set executive pay. That figure fell 13.6% from a year ago to $2.67 because last year's third quarter included a $24.5 million licensing payment from its former Pelthos unit.
Compared with the second quarter, when there was no Pelthos payment, profit per share excluding one-offs rose 12.7% from $2.37 by our math. Because the first Partial quarter with XOMA beat the pace needed for the old target, the company raised its full-year forecast to $9.50–$9.75 per share, its third raise in three quarters.
What to watch: fourth-quarter profit per share excluding one-offs against the $2.96 implied by the middle of the new full-year range. Clearing that bar would confirm the promised $0.50 second-half boost from XOMA.
Partner Pipeline Advances Toward 2027 Decisions
Because Ligand does not run clinical trials itself, its future growth depends on drug developers hitting regulatory milestones, while delays at those partners remain a constant risk. This quarter brought concrete progress across the late-stage portfolio.
- Qtorin rapamycin (a skin gel for lymphatic malformations): US regulators granted Priority Review with a February 28, 2027 decision date
- AVIM Therapy (a pacemaker-based blood pressure treatment): partner Orchestra BioMed finished pivotal trial enrollment at 330 patients, above its 316 target
- Ojemda (a brain tumor drug added via XOMA): regulators in Japan approved the medicine in September
- Zelsuvmi (a skin infection gel): partner Pelthos reported second-quarter units dispensed rose 48% from the prior quarter to 11,925
Two other programs showed why partner timelines still need watching: Rezolute must hold a preliminary meeting with US regulators before filing ersodetug, and Mirum planned extra regulatory talks before submitting volixibat. What to watch: phase 3 tumor hypoglycemia results for ersodetug due in mid-December 2026, which will test one of the nearest clinical catalysts.
🐻 Bear Case
Overhead and Stock Losses Create a GAAP Loss
“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari,” chief executive Todd Davis said. Yet under standard accounting rules, the business lost $28.5 million, or $1.43 per share.
General and administrative overhead jumped from 24.6% of total revenue a year ago to 92.2%, an increase of 67.6 percentage points by our math. That $72.6 million bill included $29.0 million in employee stock awards and $23.9 million in deal and integration fees, mostly from buying XOMA.
Even after stripping out stock awards and deal fees, underlying overhead more than doubled by our math, rising 121.6% from $8.9 million to $19.7 million due to the "expansion of Ligand’s portfolio management and origination platform to scale its royalty portfolio". Outside operations, falling share prices at partner holdings created a $35.7 million non-cash investment loss.
What to watch: underlying general and administrative expense in the fourth quarter. A reading near $20 million again would mean the larger portfolio permanently doubled cash overhead.
Release Hides How Much XOMA Added
When an acquirer folds in a large portfolio mid-quarter, investors need the underlying growth rate of the businesses it owned a year ago. The earnings release gave no dollar figure for XOMA's royalty contribution and no product breakdown for Filspari, Ohtuvayre or declining older drugs like Kyprolis.
Meanwhile, paying cash for XOMA reshaped the balance sheet. Cash and short-term investments dropped from $1.36 billion in June to $447.4 million, while convertible debt stood at $1.13 billion, leaving $680.8 million in net debt by our math. The quarterly filing, which is not yet available, usually carries the product royalty table.
What to watch: the revenue disaggregation note in the upcoming third-quarter 10-Q filing. It will show how much of the $22.3 million quarterly royalty jump came from XOMA versus existing drugs.
Captisol and Contract Targets Need a Big Q4
Outside royalties, Ligand sells Captisol, a chemical formulation ingredient used to make drugs soluble, and collects milestone payments in contract revenue. Both lines shrank this quarter, but management kept their full-year targets unchanged.
- Third-quarter Captisol sales: $7.9 million, down 25.5% from $10.7 million a year ago due to the "timing of customer orders"
- Fourth-quarter Captisol sales implied by the full-year midpoint: $12.9 million, up 65.8% from $7.8 million in last year's fourth quarter by our math
- Third-quarter contract revenue: $0.5 million, leaving $6.7 million needed in the fourth quarter to reach the $15.0 million full-year midpoint
Holding both full-year forecasts while keeping the royalty target unchanged means the fourth-quarter revenue plan leans heavily on year-end Captisol shipments and partner milestones. What to watch: fourth-quarter Captisol sales against the $10.4 million needed just to hit the $35 million bottom of the plan.
💲 Other KPIs
Financial royalty assets — acquired royalty streams accounted for as balance-sheet loans rather than intangible assets — nearly quadrupled from $219.7 million at year-end 2025 after the XOMA purchase. They also generated a $6.6 million credit-loss provision this quarter, which management excluded from adjusted profit.
Money owed by drug partners rose 39.6% from $59.6 million at the end of 2025 and climbed from $67.0 million last quarter. Because Ligand estimates royalties before partners finish reporting and collects the cash a quarter later, receivables grow alongside the expanded royalty portfolio.
The share count used to calculate profit per share excluding one-offs rose 4.5% from 20.6 million a year ago, and edged up from 21.4 million in the second quarter. Stock awards to employees outpaced the 228,859 shares repurchased during June's convertible bond sale.
🔮 Guidance
Raised. The middle of the range moved up $0.375 to $9.625, or 18.4% growth over 2025. By our math, that leaves $2.96 per share for the fourth quarter, up 46.3% from $2.02 a year ago. It is the third raise this year: +$0.50 in the first quarter, +$0.25 in the second, and +$0.375 today.
Unchanged. The middle of the range calls for $237.5 million, up 47.5% from 2025. With $161.3 million booked through September, reaching the middle requires $76.2 million in the fourth quarter by our math, or 50.9% growth over last year's $50.5 million as XOMA contributes for a full three months.
Unchanged. The $290 million middle of the range is up 8.2% against 2025 reported revenue, which included the $53.1 million Pelthos divestiture income. By our math, the plan leaves $95.8 million for the fourth quarter, up 60.6% from $59.7 million a year ago.
Unchanged. At the $37.5 million middle of the range, full-year Captisol sales would dip 6.7% from $40.2 million in 2025. After $24.6 million in the first nine months, the middle of the plan requires $12.9 million in the fourth quarter by our math, up 65.8% from $7.8 million a year ago.
Unchanged. With $8.3 million recorded through the first three quarters, Ligand needs only $1.7 million in the fourth quarter to reach the $10 million floor, but $6.7 million by our math to hit the $15 million middle of the range.
❓ Key Questions
How much third-quarter royalty revenue came from XOMA?
Royalty revenue rose $22.3 million from the second quarter to $70.3 million, and XOMA consolidated on July 14. Without a standalone XOMA figure in the release, investors cannot separate acquired revenue from underlying growth.
Why did underlying overhead more than double to $19.7 million?
Even after removing $29.0 million of stock awards and $23.9 million of deal fees, general and administrative expense jumped 121.6% from $8.9 million a year ago. Management previously expected XOMA to add less than $5 million a year in ongoing operating costs.
What triggered the $6.6 million credit-loss charge on royalties?
Ligand recorded a $6.6 million provision for expected credit losses on its financial royalty assets, up from $26,000 a year ago, and excluded the charge from adjusted profit. Management did not name which partner asset deteriorated.
Did operating cash flow stay on track for $200 million?
The earnings release did not include a cash flow statement. After generating $72.7 million in the first half, the business needed at least $127.3 million in the second half to meet management's prior full-year operating cash flow floor.